Dr. Nicolas Serafini’s group studies group 3 ILC (ILC3) biology, particularly in the context of bacterial infection and cancer. After being awarded an ANR funding, his team, which belongs to the Innate Immunity Unit, headed by Prof. James Di Santo, is looking for a junior post-doctoral researcher.
ILC3s promote the intestinal barrier integrity through the containment of beneficial commensal bacteria. These resident immune cells monitor environmental signals by scanning tissues and producing inflammatory cytokines that serve to counteract invading pathogens and preserve intestinal homeostasis. Interestingly, ILC3s also exhibit ‘memory-like’ properties that enhance their protective functions. Despite their presence in intestinal lesions, the contribution of ILC3s to inflammatory bowel disease (IBD) remains poorly understood. Throughout a lifetime, the function and fate of ILC3s appear to be strongly influenced by environmental cues, ranging from the maternal influences during gestation to host-derived signals throughout life. Understanding the mechanisms underlining imprinting processes is essential for further delineating mechanisms during chronic inflammation and disease establishment.
Here, we propose to address three key questions: How is trained immunity established in ILC3s? How can ILC3-mediated protective immunity be ensured? And how ILC3 responses could be modulated to offer new therapeutic opportunities in IBD?